This application is written in response to RFA NIH 87-IHL-06-H - Postmenopausal Estrogen/Progestin Interventions (PEPI). We propose to establish a Clinical Center at the University of Texas Health Science Center in San Antonio. The San Antonio Clinical Center will recruit 150 eligible peri and postmenopausal women in a period not to exceed 12 months. We propose to compare the effects of oral versus transdermal estrogen treatment, in the presence and in the absence of micronized progesterone. Proposed primary outcome parameters include evaluation of: endometrial histology, lipid and glucose metabolism, and symptomatology. Other suggested outcome parameters include cardiovascular effects, effects on coagulation, effects on gallbladder disease and effects on bone density.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01HL040154-05
Application #
3553188
Study Section
Special Emphasis Panel (SRC (06))
Project Start
1987-09-30
Project End
1992-07-31
Budget Start
1991-08-01
Budget End
1992-07-31
Support Year
5
Fiscal Year
1991
Total Cost
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Type
Schools of Medicine
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Barrett-Connor, Elizabeth (2005) Heart disease risk factors predict erectile dysfunction 25 years later (the Rancho Bernardo Study). Am J Cardiol 96:3M-7M
Fung, Maple M; Bettencourt, Richele; Barrett-Connor, Elizabeth (2004) Heart disease risk factors predict erectile dysfunction 25 years later: the Rancho Bernardo Study. J Am Coll Cardiol 43:1405-11
Greendale, Gail A; Espeland, Mark; Slone, Stacey et al. (2002) Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study. Arch Intern Med 162:665-72
Lindenfeld, Etta A; Langer, Robert D (2002) Bleeding patterns of the hormone replacement therapies in the postmenopausal estrogen and progestin interventions trial. Obstet Gynecol 100:853-63
Greendale, G A; Wells, B; Marcus, R et al. (2000) How many women lose bone mineral density while taking hormone replacement therapy? Results from the Postmenopausal Estrogen/Progestin Interventions Trial. Arch Intern Med 160:3065-71
Barrett-Connor, E; Espeland, M A; Greendale, G A et al. (2000) Postmenopausal hormone use following a 3-year randomized clinical trial. J Womens Health Gend Based Med 9:633-43
Cushman, M; Legault, C; Barrett-Connor, E et al. (1999) Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 100:717-22
Legault, C; Stefanick, M L; Miller, V T et al. (1999) Effect of hormone replacement therapy on the validity of the Friedewald equation in postmenopausal women: the postmenopausal estrogen/progestins interventions (PEPI) trial. J Clin Epidemiol 52:1187-95
Barnabei, V M; Phillips, T M; Hsia, J (1999) Plasma homocysteine in women taking hormone replacement therapy: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. J Womens Health Gend Based Med 8:1167-72
Greendale, G A; Reboussin, B A; Sie, A et al. (1999) Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Intern Med 130:262-9

Showing the most recent 10 out of 24 publications